Scandinavian Journal of Rheumatology最新文献_第7页

Anti-inflammatory effects of infliximab and methotrexate on peripheral blood and synovial fluid mononuclear cells: ex vivo study. 英夫利昔单抗和甲氨蝶呤对外周血和滑膜液单核细胞的抗炎作用：体外研究。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-05-01 Epub Date: 2024-01-26 DOI: 10.1080/03009742.2023.2300887

S Gertel, M Rokach, A Polachek, I Litinsky, M Anouk, O Elkayam, V Furer

{"title":"Anti-inflammatory effects of infliximab and methotrexate on peripheral blood and synovial fluid mononuclear cells: ex vivo study.","authors":"S Gertel, M Rokach, A Polachek, I Litinsky, M Anouk, O Elkayam, V Furer","doi":"10.1080/03009742.2023.2300887","DOIUrl":"10.1080/03009742.2023.2300887","url":null,"abstract":"Objective: To investigate the effects of methotrexate (MTX) and the tumour necrosis factor inhibitor infliximab (IFX) on immune cells derived from peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) of inflammatory arthritis patients.Method: Phytohaemagglutinin (PHA)-induced proliferation of healthy donors' PBMCs and synovial intermediate monocytes (CD14+CD16+ cells) in SFMCs derived from psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients was determined by flow cytometry following co-culture with IFX and MTX. PHA-induced interferon-γ (IFN-γ) production in PBMCs was measured by enzyme-linked immunosorbent assay. The drugs' effect on mRNA expression in SFMCs was determined by quantitative polymerase chain reaction.Results: The combination of IFX 10 μg/mL + MTX 0.1 μg/mL had the strongest inhibitory effect on PBMC proliferation (91%), followed by MTX 0.1 μg/mL (86%) and IFX 10 μg/mL (49%). In PHA-stimulated PBMCs, IFN-γ production was reduced by IFX 10 μg/mL, MTX 0.1 μg/mL, and IFX 10 μg/mL + MTX 0.1 μg/mL by 68%, 90%, and 85%, respectively. In SFMCs, IFX 10 µg/mL significantly reduced CD14+CD16+ cells compared to medium (PsA 54%, p < 0.01; RA 46%, p < 0.05), while MTX had no effect on this population. IFX + MTX led to a similar suppression of CD14+CD16+ cells as achieved by IFX alone. The drugs had different impacts on SFMC gene expression.Conclusion: Both IFX and MTX effectively inhibited PBMC proliferation and IFN-γ production, but only IFX reduced synovial monocytes and pro-inflammatory gene expression in SFMCs, suggesting a differential impact of IFX and MTX on critical inflammatory cell populations ex vivo.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"188-198"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Follicular lymphoma: an unexpected cause of adhesive capsulitis. 滤泡淋巴瘤：粘连性囊炎的意外病因。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-05-01 Epub Date: 2024-01-26 DOI: 10.1080/03009742.2023.2299630

I C Neves Dos Santos, M Henriques Castro, M Fernandes Diz Lopes, C A Marques Gomes, Mlc Dias Costa, R M Dos Santos Ferreira

引用次数: 0

Refractory systemic lupus erythematosus with neuropsychiatric manifestations successfully treated with anifrolumab. 用安非罗单抗成功治疗了伴有神经精神症状的难治性系统性红斑狼疮。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-05-01 Epub Date: 2024-01-26 DOI: 10.1080/03009742.2024.2306053

Y Kobayashi, S Hanai, T Iwamoto, D Nakagomi

引用次数: 0

Polyarthritis due to metastatic calcinosis in a patient with new WT1 gene mutation: resolution after renal transplantation. 一名新WT1基因突变患者因转移性钙化引起的多关节炎：肾移植后缓解。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-05-01 Epub Date: 2024-01-15 DOI: 10.1080/03009742.2023.2299610

F Rajão Martins, F Gonçalves, A Guedes, G Sequeira, C Ribeiro

引用次数: 0

Population-based epidemiological projections of rheumatoid arthritis in Germany until 2040. 基于人口的 2040 年前德国类风湿关节炎流行病学预测。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-05-01 Epub Date: 2024-02-15 DOI: 10.1080/03009742.2024.2312693

J Wang, S Vordenbäumen, M Schneider, R Brinks

{"title":"Population-based epidemiological projections of rheumatoid arthritis in Germany until 2040.","authors":"J Wang, S Vordenbäumen, M Schneider, R Brinks","doi":"10.1080/03009742.2024.2312693","DOIUrl":"10.1080/03009742.2024.2312693","url":null,"abstract":"Objectives: Our aim was to conduct a population-based projection to estimate the number of rheumatoid arthritis (RA) cases in Germany until 2040.Method: Data obtained from a report published in 2017 (doi:10.20364/VA-17.08) were used for future prediction analysis. The data were originally collected by the German Central Institute for Statutory Health Insurance. We used the illness-death model to estimate future numbers of RA cases, considering nine possible scenarios based on different incidence and mortality rates.Results: In the baseline scenario, the number of women with RA is projected to increase by 417 000 cases and men by 179 000 cases by 2040, compared with 2015. Peak numbers of cases are concentrated in the 70-80-year-old age group, particularly among women. In the most favourable scenario (scenario 2), assuming a decreasing incidence, the total number of RA cases is projected to rise by 284 000 by 2040, reflecting a 38% relative increase from 2015 to 2040. The least favourable scenario (scenario 9), assuming an increasing incidence, projects a significant burden on the healthcare system. The total number of RA cases is expected to rise by 1.16 million by 2040, marking a substantial 158% relative increase from 2015 to 2040.Conclusions: Our research emphasizes a discernible trend: with an ageing society, improving treatment effectiveness, and declining all-cause mortality, we anticipate a rise in the absolute numbers of RA cases in Germany in the coming years. Our models robustly support this viewpoint, underscoring impending challenges for healthcare systems. Addressing these challenges demands multifaceted interventions.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"161-172"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rheumatoid arthritis with chylothorax: a case report 类风湿性关节炎伴有乳糜胸：病例报告

IF 2.1 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-04-30 DOI: 10.1080/03009742.2024.2342053

Z Li, S Lei, S Zhou, Z Zhang

引用次数: 0

Sick leave and disability pension following delivery in women with systemic lupus erythematosus 患有系统性红斑狼疮的妇女分娩后的病假和残疾抚恤金

IF 2.1 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-04-12 DOI: 10.1080/03009742.2024.2321057

D Grannas, JF Simard, E Svenungsson, EV Arkema, SAM Gernaat

引用次数: 0

Immunoglobulin G/immunoglobulin M autoantibody ratios in incomplete systemic lupus erythematosus 不完全性系统性红斑狼疮的免疫球蛋白 G/ 免疫球蛋白 M 自身抗体比率

IF 2.1 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-03-20 DOI: 10.1080/03009742.2024.2321700

S Henning, J Westra, C Roozendaal, G Haarsma-de Boer, JJ Fierro, B Horvath, H Bootsma, K de Leeuw

引用次数: 0

Physical activity in adults with and without rheumatoid arthritis: cross-sectional results from the Survey of Health, Ageing and Retirement in Europe (SHARE). 患有和不患有类风湿性关节炎的成年人的体育活动：欧洲健康、老龄化和退休调查（SHARE）的横断面结果。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-03-01 Epub Date: 2023-10-31 DOI: 10.1080/03009742.2023.2269672

M H Belau, F Flaßkamp, H Becher, A Hajek, H-H König, L Baumbach

{"title":"Physical activity in adults with and without rheumatoid arthritis: cross-sectional results from the Survey of Health, Ageing and Retirement in Europe (SHARE).","authors":"M H Belau, F Flaßkamp, H Becher, A Hajek, H-H König, L Baumbach","doi":"10.1080/03009742.2023.2269672","DOIUrl":"10.1080/03009742.2023.2269672","url":null,"abstract":"Objective: Studies examining habitual physical activity levels and patterns in adults with rheumatoid arthritis (RA) using raw data from modern accelerometers are lacking. We aimed (i) to examine physical activity levels and patterns in adults with RA in their familiar environment, and (ii) to investigate whether physical activity levels differ throughout the day.Method: Data were taken from Wave 8 of the Survey of Health, Ageing and Retirement in Europe, including N = 607 men and women who wore a triaxial accelerometer and had adequate information for RA and accelerometry data summarized as Euclidean norm minus one (ENMO, mg). Growth-curve models and simple contrast analysis were used to examine the effect of RA on daily patterns of physical activity levels, including mean total ENMO in mg, mean minutes of light-intensity physical activity (ENMO values ≥ 25 mg and ≤ 75 mg), and moderate-to-vigorous-intensity physical activity (ENMO values > 75 mg).Results: Total physical activity averaged throughout the day was 25.0 and 28.6 mg for respondents with and without RA, respectively. Respondents with RA spent more time in light-intensity physical activity throughout the day (p < 0.001), but less time in moderate-to-vigorous-intensity physical activity between 4 am and 11 pm (p < 0.001) than respondents without RA.Conclusion: Adults with RA were less physically active than adults without RA. However, there were no diurnal differences in physical activity.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"112-117"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71413813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control? 银屑病关节炎开始抗肿瘤坏死因子治疗后持续疼痛及其预测因素:炎症控制的作用是什么?

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-03-01 Epub Date: 2023-11-30 DOI: 10.1080/03009742.2023.2258644

C Roseman, J K Wallman, A Jöud, Mec Schelin, J T Einarsson, E Lindqvist, J Lampa, M C Kapetanovic, T Olofsson

{"title":"Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?","authors":"C Roseman, J K Wallman, A Jöud, Mec Schelin, J T Einarsson, E Lindqvist, J Lampa, M C Kapetanovic, T Olofsson","doi":"10.1080/03009742.2023.2258644","DOIUrl":"10.1080/03009742.2023.2258644","url":null,"abstract":"Objective: While considerable focus has been placed on pain due to inflammation in psoriatic arthritis (PsA), less is reported on pain despite inflammation control. Here, we aimed to investigate the occurrence/predictors of persistent pain, including non-inflammatory components, after starting anti-tumour necrosis factor (anti-TNF) therapy.Method: Bionaïve PsA patients starting a first anti-TNF therapy 2004-2010 were identified (South Swedish Arthritis Treatment Group register; N = 351). Outcomes included unacceptable pain [visual analogue scale (VAS) pain > 40 mm], and unacceptable pain despite inflammation control (refractory pain; VAS pain > 40 mm + C-reactive protein < 10 mg/L + ≤ 1 swollen joint of 28), assessed at 0, 3, 6, and 12 months. Baseline predictors were estimated by logistic regression.Results: Upon starting anti-TNF therapy, 85% of patients reported unacceptable pain, falling to 43% at 3 months and then remaining stable. After 12 months, refractory pain constituted 63% of all unacceptable pain. Higher baseline VAS pain/global, worse physical function and lower health-related quality-of-life were associated with a higher risk of unacceptable/refractory pain at 12 months. More swollen joints and higher evaluator's global assessment were associated with a lower risk of 12-month refractory pain.Conclusions: A substantial proportion of PsA patients reported unacceptable pain throughout the first anti-TNF treatment year. At 12 months, refractory pain constituted about two-thirds of this remaining pain load. More objective signs of inflammation at anti-TNF initiation were associated with less future refractory pain. This highlights insufficient effect of biologics in patients with inflammation-independent pain, warranting alternative treatments.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"94-103"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0